Racial Disparities in Colorectal Cancer Survival: Is Elimination of Variation in Care the Cure?

Journal of the National Cancer Institute

Volumn 107, Issue 10, 2015, Pages

  Doubeni, Chyke A ^a   Rustgi, Anil ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; FOLINIC ACID; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; OXALIPLATIN;

ANCESTRY GROUP; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; COLORECTAL CANCER; CPG ISLAND; DISEASE FREE SURVIVAL; EDITORIAL; ENVIRONMENTAL EXPOSURE; EVIDENCE BASED PRACTICE; GENE MUTATION; GENOTYPE ENVIRONMENT INTERACTION; HEALTH CARE DELIVERY; HEALTH DISPARITY; HEALTH SERVICE; HUMAN; MISMATCH REPAIR; PATIENT CARE; PRESCRIPTION; PRIORITY JOURNAL; PROMOTER REGION; PUBLIC HEALTH PROBLEM; RACE DIFFERENCE; RACISM; SOCIAL STATUS; COLORECTAL TUMOR; ETHNOLOGY; HEALTH CARE DISPARITY; MORTALITY; TRENDS;

COLORECTAL NEOPLASMS; CONTINENTAL POPULATION GROUPS; HEALTHCARE DISPARITIES; HUMANS;

EID: 84944685066     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djv229     Document Type: Editorial

References (11)

1. DeSantis C, Naishadham D, Jemal A. Cancer statistics for African Americans, 2013. CA Cancer J Clin. 2013;63(3):151-166.
2. Carethers JM. Screening for colorectal cancer in African Americans: determinants and rationale for an earlier age to commence screening. Dig Dis Sci. 2015;60(3):711-721.
3. Bogaert J, Prenen H. Molecular genetics of colorectal cancer. Ann Gastroenterol. 2014;27(1):9-14.
4. Lichtenstein P, Holm NV, Verkasalo PK, et al. Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med. 2000;343(2):78-85.
5. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359(17):1757-1765.
6. Doubeni CA, Field TS, Buist DS, et al. Racial differences in tumor stage and survival for colorectal cancer in an insured population. Cancer. 2007;109(3):612-620.
7. Kumar K, Brim H, Giardiello F, et al. Distinct BRAF (V600E) and KRAS mutations in high microsatellite instability sporadic colorectal cancer in African Americans. Clin Cancer Res. 2009;15(4):1155-1161.
8. Yoon, HH, Shi Q, Alberts SR, et al. Racial differences in BRAF/KRAS mutation rates and survival in stage III colon cancer patients. J Natl Cancer Inst. 2015. 107(10):djv186 doi:10.1093/jnci/djv186.
9. Prahallad A, Sun C, Huang S, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature. 2012;483(7387):100-103.
10. Rustgi AK. BRAF: a driver of the serrated pathway in colon cancer. Cancer Cell. 2013;24(1):1-2.
11. Cancer Genome Atlas N. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487(7407):330-337.